Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 9/20 | 1.00 |
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | PKLR | P30613 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL932094 | 0.98 | PKM (0.97) | PKMMCOLN3TSHRLMNAMEN1 | |
| SCHEMBL6793698 | 0.94 | PKM (0.89) | PKMMCOLN3TSHRLMNAMEN1 | |
| Hydrochloric Acid SCHEMBL9780283 | 0.89 | PKM (0.79) | PKMMCOLN3TSHRLMNAMEN1 | |
| SCHEMBL18134604 | 0.88 | MCOLN3 (0.83) | PKMMCOLN3TSHRLMNAMEN1 | |
| SCHEMBL30754647 | 0.88 | PKM (0.78) | PKMMCOLN3TSHRLMNAMEN1 | |
| SCHEMBL12344078 | 0.86 | PKM (0.75) | PKMMCOLN3TSHRLMNAMEN1 | |
| SCHEMBL3169939 | 0.85 | MCOLN3 (0.97) | PKMMCOLN3TSHRLMNAMEN1 | |
| SCHEMBL5204276 | 0.84 | PKM (0.73) | PKMMCOLN3TSHRMEN1KMT2A | |
| SCHEMBL2266915 | 0.84 | PKM (0.73) | PKMMCOLN3TSHRMAPT | |
| SCHEMBL12341270 | 0.83 | PKM (0.71) | PKMMCOLN3TSHRLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448581-B1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9115086-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115086-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-8865720-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | disclosed |
| US-8703957-B2 | Phosphonic acid compounds as inhibitors of serine proteases | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-22 | — | — | US | disclosed |
| US-8703957-B2 | Phosphonic acid compounds as inhibitors of serine proteases | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-22 | — | — | US | disclosed |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-06 | — | — | US | disclosed |
| US-20130281407-A1 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281407-A1 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-24 | — | — | US | disclosed |
| US-8557825-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2002-08-29 | — | — | US | disclosed |
| US-6225309-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2001-05-01 | — | — | US | disclosed |
| CN-1272107-A | Benzamidine derivatives as factor Xa inhibitors | MERCK PATENT GMBH (DE) | 2000-11-01 | — | — | CN | disclosed |
| US-6030946-A | FUNCTIONS REVERSIBLY, RESULTING IN TIGHT BINDING (LOW DISSOCIATION CONSTANTS) BETWEEN INHIBITOR AND TARGET ENZYME; USED TO TREAT VARIETY OF DISEAES, INCLUDING ARTHRITIS, MUSCULAR DYSTROPHY, INFLAMMATION, TUMOR INVASION, MALERIA | AXYS PHARMACEUTICALS, INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-5965559-A | STRONG INHIBITORY EFFECT AGAINST THE ACTIVATED COAGULATION PROTEASE KNOWN AS FACTOR XA; PREVENTION OF THE CLEAVAGE OF PROTHROMBIN TO THROMBIN; AMINO-SUBSTITUTED PYRIMIDINES AMIDINE GROUP-FREE | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| EP-0783500-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
| EP-0832099-A1 | REVERSIBLE CYSTEINE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996040737-A1 | REVERSIBLE CYSTEINE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | PKM 424/4885MCOLN3 3686/4885TSHR 773/4885 |
| US-20130281407-A1 | NOVEL PHOSPHONIC ACID COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | HPN, PRSS1, SERPINB1 | PKM 1978/4885MCOLN3 3473/4885TSHR 4753/4885 |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | SERPINC1, F2, SULT1E1 | PKM 4658/4885MCOLN3 1309/4885TSHR 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.